A phase 1b clinical trial of cabozantinib (CABO) and abiraterone (ABI) with checkpoint inhibitor immunotherapy (CPI) in metastatic hormone-sensitive prostate cancer (mHSPC) (CABIOS Trial).

Authors

Melissa Andrea Reimers

Washington University in St. Louis, St. Louis, MO

Melissa Andrea Reimers , John Louis Visconti , Giordano Fabricio Cittolin Santos , Russell Kent Pachynski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

First Author: Neeraj Agarwal

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).

First Author: Sumanta K. Pal

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).

First Author: Jesse Meir Zaretsky

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

First Author: Karim Fizazi